PTEN and prostate carcinoma: Furthermore, in our PTEN deficient prostate cancer models (LNCaP, MSKPCa1, and MSKPCa3) a similar phenotype of residual rebound PI3K signaling is observed following combined p110α and p110β inhibition (Fig. 3a, c and Supplementary Fig. 3D).